alexa Pioglitazone in Combination with Insulin – An Overview of Results from PROactive
Pharmaceutical Sciences

Pharmaceutical Sciences

Research & Reviews: Journal of Hospital and Clinical Pharmacy

Author(s): Bernard Charbonnel

Abstract Share this page

Pioglitazone provides one of several add-on therapy options for patients with unsatisfactory glycaemic control treated with insulin. Although pioglitazone has the beneficial feature of low hypoglycaemia risk, it has an overlapping adverse event profile with insulin in terms of oedema (with the potential to exacerbate heart failure) and weight gain, leading to possible concern over their use in combination. Fortunately, subgroup analyses from the PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) have provided valuable insights into the efficacy and safety profile of pioglitazone in patients on established insulin therapy. Pioglitazone improved glycaemic control and lipids, while enabling patients to reduce their insulin requirements. Oedema and weight were predictable with no excess exacerbation of heart failure with the combination. Importantly, pioglitazone had a good macrovascular safety profile (with a trend towards benefit), consistent with the overall population. This article provides an overview of the results from the insulin-treated subgroup in PROactive and highlights some of the clinical implications for pioglitazone–insulin combination therapy.

This article was published in European Endocrinology and referenced in Research & Reviews: Journal of Hospital and Clinical Pharmacy

Relevant Expert PPTs

Relevant Speaker PPTs

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version